Trägärdh B, Lynch P R
Invest Radiol. 1978 May-Jun;13(3):233-7. doi: 10.1097/00004424-197805000-00009.
Metrizamide (non-ionic, Nyegaard Co., Oslo, Norway), diatrizoate (ionic) and metrizoate (ionic) were selectively injected into the right or the left canine coronary artery. ECG was recorded and external defibrillation was performed whenever ventricular fibrillation occurred. During left coronary injections metrizamide prolonged the PQ and QT intervals less than did the diatrizoate. During right coronary injections metrizamide affected the QT interval less than either diatrizoate and metrizoate. During right coronary infusions metrizamide caused significantly fewer incidences of ventricular fibrillation than diatrizoate. In clinical coronary arteriography it is assumed that metrizamide would generate fewer AV blocks than diatrizoate and fewer incidences of ventricular fibrillation after right coronary injections than diatrizoate. Changes in the PQ and QT intervals during coronary arteriography can be used as tests to predict the safety of new contrast media.
将甲泛葡胺(非离子型,挪威奥斯陆Nyegaard公司生产)、泛影葡胺(离子型)和碘异肽醇(离子型)选择性地注入犬的右冠状动脉或左冠状动脉。记录心电图,一旦发生心室颤动即进行体外除颤。在左冠状动脉注射期间,甲泛葡胺延长PQ和QT间期的程度小于泛影葡胺。在右冠状动脉注射期间,甲泛葡胺对QT间期的影响小于泛影葡胺和碘异肽醇。在右冠状动脉输注期间,甲泛葡胺引起心室颤动的发生率明显低于泛影葡胺。在临床冠状动脉造影中,推测甲泛葡胺产生的房室传导阻滞少于泛影葡胺,右冠状动脉注射后发生心室颤动的发生率也低于泛影葡胺。冠状动脉造影期间PQ和QT间期的变化可作为预测新型造影剂安全性的测试。